摘要
目的:观察国产多西紫杉醇联合化疗治疗乳腺癌转移瘤的临床疗效、不良作用和临床受益反应(clinical benefit response,CBR)。方法:30例乳腺癌转移瘤患者,既往未用过蒽环类药物治疗的14例患者采用多西紫杉醇联合阿霉素化疗;既往蒽环类药物治疗失败的16例患者采用多西紫杉醇联合卡培他滨化疗;每21天重复,2周期评价疗效,记录不良作用。结果:总有效率(CR+PR)66.7%,肿瘤控制率(CR+PR+SD)93.3%。主要毒副作用为骨髓抑制和脱发。CBR评价有效者73.3%。结论:国产多西紫杉醇联合化疗治疗乳腺癌转移瘤有较好疗效,不良作用可耐受,临床受益反应良好。
Objective ：To evaluate the clinical efficacy, side effects and clinical benefit response of domestic docetaxel - based combination chemotherapy in the treatment of metastatic breast cancer. Methods： Thirty patients were enrolled into this study. Fourteen metastatic breast cancer patients without anthracycline -pretreated were treated with docetaxel and doxorubicin. Sixteen metastatic breast cancer patients with anthracycline - pretreated were treated with docetaxel and capecitabine（Xeloda）. Two or more therapatic courses were conducted with an interval of 21 days. Efficacy, side effects and clinical benefit response were recorded in every 2 cycles. Results： The total response rate （CR ＋ PR） was 66.7%. The tumor control rate （CR ＋ PR ＋ SD） was 93.3%. The side effects were slight, including bone marrow suppression and alopecia. The clinical benefit response was 73.3%. Conclusion： Domestic docetaxel -based combination chemotherapy is effective for metastatic breast cancer.
出处
《现代肿瘤医学》
CAS
2008年第4期579-580,共2页
Journal of Modern Oncology
